Everest Medicines Ltd. has obtained IND clearance from the FDA for EVM-14, an off-the-shelf mRNA cancer vaccine targeting multiple tumor-associated antigens and designed to treat various cancers, including non-small-cell lung cancer and head and neck cancer.
Esophageal squamous cell carcinoma (ESCC) accounts for about 90% of esophageal cancer cases and is the sixth most common cause of cancer death worldwide. Targeting cancer stem cells offers a therapeutic approach for addressing cancer, concretely in those cases that are resistant to cisplatin.
Scientists at the Institute of Cancer Research (ICR) in the U.K. are developing a technology that analyzes, in vitro, how the 3D morphology of cancer cells changes when exposed to a compound, using AI to predict their response to new treatments. The researchers estimate that their methodology could accelerate drug development by 6 years, by ruling out unsuccessful drugs and thus reducing the number of preclinical trials.
Eikon Therapeutics Inc. has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Anaplastic thyroid cancer (ATC) is a rare but aggressive form of thyroid cancer, accounting for nearly 50% of thyroid cancer-related deaths. Given its poor prognosis, the identification of new therapeutic strategies is a critical medical need. Molecular radiotherapy is an emerging field in oncology, and CD44v6, a cell surface antigen overexpressed in several cancers, has been proposed as a promising target for ATC treatment.
Researchers from Abl Bio Inc. have published preclinical data for ABL-112, an Fc-competent bispecific antibody (BsAb) targeting TIGIT and 4-1BB (TIGIT x 4-1BB), being developed for the treatment of cancer.
Marengo Therapeutics Inc. has entered into a multiyear research collaboration in oncology and autoimmune diseases with University of Pennsylvania Perelman School of Medicine. The research collaboration will provide deeper insights into the mechanism of action of Marengo’s selective dual T-cell agonists in oncology.
Axcynsis Therapeutics Pte Ltd. has described antibody-drug conjugates comprising an antibody or antigen-binding fragment targeting alkaline phosphatase placental type (ALPP) and/or alkaline phosphatase, germ cell type (ALPPL2) covalently linked to a cytotoxic agent through a linker reported to be useful for the treatment of cancer.
RSS
